Form 4: Protara Therapeutics Executive Acquires Shares and Stock Options
SEC Form 4
Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, reports acquisition of common stock and stock options.
Summary
- On January 24, 2025, Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, acquired 24,500 shares of common stock through restricted stock units (RSUs).
- These RSUs vest in equal one-third installments annually, starting January 24, 2025.
- Zummo also acquired stock options for 146,000 shares at an exercise price of $4.53.
- 25% of these options vest on January 24, 2026, with the remainder vesting monthly over the subsequent three years, contingent upon continuous service.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports insider transactions, which can be interpreted as either positive (confidence in the company) or neutral (part of a standard compensation package).
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive sign of confidence in the company's future.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- Shareholders may view the insider's stock acquisition as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of transaction: Acquisition of common stock and stock options. |
| 01/24/2025 | First vesting date for RSUs. |
| 01/24/2026 | First vesting date for 25% of the stock options. |
| 01/23/2035 | Expiration date for the stock options. |
| 01/28/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.